Skip to main content
. 2019 Aug 24;26(3):1499–1510. doi: 10.1007/s12253-019-00726-w

Fig. 2.

Fig. 2

Comparison of the PFS (a) and OS (b) of patients in Group IV (containing patients with high MCM2, high Cyclin A and high PHH3 expression) vs. the other investigated patient groups (Group I, II, III and V)